Does GGPeps issue lot-specific documentation, or a batch certificate?

I have both a purity figure and a content figure, which is why the discrepancy is visible.

I want to understand what this actually establishes, as opposed to what it is being used to imply.

My concern is that I am being invited to draw a conclusion the data does not support.

What is the correct interpretation, and what is the common misreading?

Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Specifically, a statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 26 Jan 2026 by h_pergande — corrected a unit error in the worked example

It helps to be literal here: sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

If testing multiple vials, state how many you tested and why you chose those vials.

The part that matters: if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

Most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.